Stylopoulos N, Gazelle GS, Rattner DW
Loading phase protocol (acute injury or initial treatment): Dose: 500 mcg to 1 mg per injection Frequency: Once daily Duration: 7 to 10 days Injection site: Subcutaneous, ideally near the area of concern Timing: Morning or evening, consistency matters more than specific time Maintenance phase protocol: Dose: 500 mcg to 1 mg per injection Frequency: 2 to 3 times per week Duration: 4 to 8 weeks total protocol length Cycle recommendation: 2 months on, 2 months off Unlike traditional BPC-157 acetate, which is often administered twice daily due to its shorter half-life, the enhanced stability of the arginate form typically allows for once-daily dosing during the loading phase
To protect against damage to our cells from oxidative stress, we naturally produce an antioxidant called glutathione
The difference between research-grade and clinical-grade is not marketing language
Every batch of BPC157 is third-party tested, and COAs are provided to confirm purity levels above 99%
Nie naley rwnie stosowa produktu w aden inny sposb u ludzi lub zwierzt, a jedynie zgodnie z jego przeznaczeniem
